Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PLXthis companyProtalix BioTherapeutics, Inc.	$2.51	-21.4×	2.93×	2.68×	-45.74×	-235.1%	47.8%	-10.4%	-12.5%	-13.7%	-9.6%	-9.6%	0.17×	2.15×	-4.62×	2.51×	0.0%	4	0.74	4	A-
PLYXPolaryx Therapeutics, Inc. Common Stock	$1.83	-184.21×	362.98×	0×	-183.85×	-94.3%	0.0%	0.0%	0.0%	-196.8%	-162.4%	-0.2%	0×	0.57×	0×	8.55×	0.0%	3	46.88	1	D+
RAREUltragenyx Pharmaceutical Inc.	$15.50	-3.95×	-28.35×	3.37×	-6.56×	-2636.3%	83.8%	-79.5%	-85.4%	718.8%	-43.5%	-20.8%	-15.95×	-1.78×	-8.63×	2.48×	0.0%	2	-5.22	2	B-
Peer median	—	-94.08×	167.32×	1.68×	-95.2×	-1365.3%	41.9%	-39.7%	-42.7%	261.0%	-103.0%	-10.5%	-7.98×	-0.6×	-4.31×	5.51×	0.0%	3	20.83	2	—